Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)

Simply Wall St.05-22

Earlier this month, EyePoint Pharmaceuticals reported that an independent safety committee completed its third review of the pivotal Phase 3 DURAVYU wet AMD trials and advised that the LUGANO and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637365690?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-05-22 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637365690","market":"us","top_or_hot":-1,"title":"Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, EyePoint Pharmaceuticals reported that an independent safety committee completed its third review of the pivotal Phase 3 DURAVYU wet AMD trials and advised that the LUGANO and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/phase-3-duravyu-safety-green-light-might-change-the-case-for\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-22 07:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/phase-3-duravyu-safety-green-light-might-change-the-case-for><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, EyePoint Pharmaceuticals reported that an independent safety committee completed its third review of the pivotal Phase 3 DURAVYU wet AMD trials and advised that the LUGANO and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/phase-3-duravyu-safety-green-light-might-change-the-case-for\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/phase-3-duravyu-safety-green-light-might-change-the-case-for","article_id":"2637365690","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/phase-3-duravyu-safety-green-light-might-change-the-case-for","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637365690","pubTimestamp":1779406420,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, EyePoint Pharmaceuticals reported that an independent safety committee completed its third review of the pivotal Phase 3 DURAVYU wet AMD trials and advised that the LUGANO and LUCIA studies proceed as planned, with no protocol changes and a safety profile consistent with prior studies in over 190 patients.\nThis progress, with all treated patients having received at least a second six‑month DURAVYU dose and over 35% reaching a third, underscores how close the program is to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","EYPT":"EyePoint","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"DURAVYU第三阶段安全绿灯可能会改变投资EyePoint(EYPT)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1.5},"content_text":"Earlier this month, EyePoint Pharmaceuticals reported that an independent safety committee completed its third review of the pivotal Phase 3 DURAVYU wet AMD trials and advised that the LUGANO and LUCIA studies proceed as planned, with no protocol changes and a safety profile consistent with prior studies in over 190 patients. This progress, with all treated patients having received at least a second six‑month DURAVYU dose and over 35% reaching a third, underscores how close the program is to topline data and potential regulatory milestones in a highly competitive retinal disease market. We’ll now examine how the DSMC’s endorsement of DURAVYU’s ongoing Phase 3 program may influence EyePoint’s existing investment narrative. Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.AdvertisementEyePoint Investment Narrative RecapTo own EyePoint, you need to believe DURAVYU can transition the company from minimal current revenue to a viable retinal franchise, despite heavy losses and reliance on a single asset. The DSMC’s clean third review does not change the basic risk that topline Phase 3 wet AMD data remain the key near term catalyst and the main potential breaking point for the story. The recent decision to grant stock options to new employees at US$12.35 per share is small beside the company’s clinical milestones, but it does underscore EyePoint’s ongoing investment in talent as it moves toward pivotal readouts and, potentially, a commercial build around DURAVYU. Yet in contrast, investors should still weigh how EyePoint’s limited current revenue and dependence on DURAVYU could magnify any unexpected delay or disappointment... Read the full narrative on EyePoint (it's free!)EyePoint's narrative projects $334.0 million revenue and $60.6 million earnings by 2029.Uncover how EyePoint's forecasts yield a $37.00 fair value, a 190% upside to its current price.Exploring Other PerspectivesEYPT 1-Year Stock Price Chart Some of the most optimistic analysts were already assuming revenue could reach about US$250.8 million by 2028, which is far more bullish than consensus, and they viewed EyePoint’s rapid execution as a clear advantage. This new DSMC update may either reinforce that confidence or prompt revisions, depending on how you interpret the same trial progress and the risk of future dilution.Explore 3 other fair value estimates on EyePoint - why the stock might be worth over 6x more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your EyePoint research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.Our free EyePoint research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.Looking For Alternative Opportunities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.Uncover the next big thing with 28 elite penny stocks that balance risk and reward.The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if EyePoint might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637365690","isCrawlerRequest":true}